New combo attack on liver cancer: drug activated by Tumor's own hypoxia

NCT ID NCT02174549

Recruiting now Disease control Sponsor: Teclison Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a drug called tirapazamine, which becomes active only in low-oxygen (hypoxic) areas of tumors, combined with a standard procedure that blocks blood flow to the tumor (transarterial embolization). The goal is to find the best dose and see if the combination is safe and can shrink liver tumors. The study includes up to 25 adults with liver cancer or neuroendocrine tumors that have spread to the liver.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: tirapazamine
What this could lead to: If it works, this could point toward a new treatment option for liver cancer and neuroendocrine tumors that have spread to the liver.
What could go wrong: This is a very early, small trial (25 people) focused on safety and dosing. The drug may not shrink tumors or could cause side effects. Success is far from guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system cancer hepatocellular carcinoma Hypoxia neuroendocrine neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTROINTESTINAL CANCER METASTATIC HEPATOCELLULAR CARCINOMA NEUROENDOCRINE TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Stanford University
RECRUITING

Palo Alto, California, 94305, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.